Eric D. Weinhandl
Research Subjects
Eric D. Weinhandl has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- James B. Wetmore
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
7 shared publications David T. Gilbertson
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, USA
6 shared publications- Kirsten L. Johansen
Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota
6 shared publications Paul Komenda
Section of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Canada; Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada; Seven Oaks General Hospital Renal Program, Winnipeg, Canada
4 shared publicationsPeter A. McCullough
Baylor University Medical Center, Dallas, TX; Baylor Heart and Vascular Institute, Dallas, TX; Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX; The Heart Hospital Baylor Plano, Plano, TX
4 shared publicationsGeorge L. Bakris
American Society of Hypertension Comprehensive Hypertension Center, Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Chicago Medicine, Chicago, IL
3 shared publications
Latest Publications
- 25 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 1928-1935
Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD
Key Points: Glucagon-like peptide-1 receptor agonist have shown clinical benefits in patients with chronic kidney disease, but there are no randomized trials to support their efficacy in ESKD. This matched retrospective cohort study used electronic health record from a dialysis provider and was conducted in diabetic, incident in-center hemodialysis patients. Results indicated that continued use of glucagon-like peptide-1 receptor agonist is associated with a 9% lower hospitalization and a 17% lower mortality rate. Background: The recent clinical trial FLOW showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduced the risk of clinical outcomes and death from cardiovascular causes in patients with CKD and type 2 diabetes. Given the substantial benefit to patients with CKD, the question remains whether these drugs benefit patients with ESKD. We sought to evaluate the impact of GLP-1 RA use in patients with incident ESKD on clinical outcomes. Methods: Patients included in this matched retrospective cohort study were adult patients with ESKD who initiated thrice-weekly in-center hemodialysis at a kidney care organization between January 2018 and April 2024. Using internal electronic health record data, eligible patients who initiated dialysis on a GLP-1 RA (with evidence of a GLP-1 RA prescription in the first 30 days after dialysis initiation; n =2492) were matched 1:1 to those not on a prescription. Patients were followed from index date until death or the end of the study (July 31, 2024). Incident rate ratios were estimated using a negative binomial distribution with a random intercept to account for the matched nature of the data. Results: Patients with a GLP-1 RA prescription in the first month of dialysis had a mean±SD age of 63±12 years and were predominately male (59%). Compared with other eligible dialysis patients, nearly all patients on a GLP-1 RA had a known diagnosis of diabetes (98% versus 73%), a majority had evidence of predialysis nephrology care (76% versus 67%), were of White race (46% versus 39%), and had a mean±SD body mass index of 33±8 kg/m 2 (versus 30±8). After matching and adjustment, GLP-1 RAs were independently associated with lower hospitalization (incidence rate ratios, 0.91 [0.87 to 0.96]) and mortality (Incidence rate ratios, 0.83 [0.73 to 0.95]) rates. Conclusions: Among incident in-center hemodialysis patients, GLP-1 RA use was independently associated with a 9% lower hospitalization rate and a 17% lower mortality rate.
- 25 August 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (11) , 1928-1935
Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with ESKD
Key Points: Glucagon-like peptide-1 receptor agonist have shown clinical benefits in patients with chronic kidney disease, but there are no randomized trials to support their efficacy in ESKD. This matched retrospective cohort study used electronic health record from a dialysis provider and was conducted in diabetic, incident in-center hemodialysis patients. Results indicated that continued use of glucagon-like peptide-1 receptor agonist is associated with a 9% lower hospitalization and a 17% lower mortality rate. Background: The recent clinical trial FLOW showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), reduced the risk of clinical outcomes and death from cardiovascular causes in patients with CKD and type 2 diabetes. Given the substantial benefit to patients with CKD, the question remains whether these drugs benefit patients with ESKD. We sought to evaluate the impact of GLP-1 RA use in patients with incident ESKD on clinical outcomes. Methods: Patients included in this matched retrospective cohort study were adult patients with ESKD who initiated thrice-weekly in-center hemodialysis at a kidney care organization between January 2018 and April 2024. Using internal electronic health record data, eligible patients who initiated dialysis on a GLP-1 RA (with evidence of a GLP-1 RA prescription in the first 30 days after dialysis initiation; n =2492) were matched 1:1 to those not on a prescription. Patients were followed from index date until death or the end of the study (July 31, 2024). Incident rate ratios were estimated using a negative binomial distribution with a random intercept to account for the matched nature of the data. Results: Patients with a GLP-1 RA prescription in the first month of dialysis had a mean±SD age of 63±12 years and were predominately male (59%). Compared with other eligible dialysis patients, nearly all patients on a GLP-1 RA had a known diagnosis of diabetes (98% versus 73%), a majority had evidence of predialysis nephrology care (76% versus 67%), were of White race (46% versus 39%), and had a mean±SD body mass index of 33±8 kg/m 2 (versus 30±8). After matching and adjustment, GLP-1 RAs were independently associated with lower hospitalization (incidence rate ratios, 0.91 [0.87 to 0.96]) and mortality (Incidence rate ratios, 0.83 [0.73 to 0.95]) rates. Conclusions: Among incident in-center hemodialysis patients, GLP-1 RA use was independently associated with a 9% lower hospitalization rate and a 17% lower mortality rate.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1786-1788
Risk of Vascular Access–Related Infections in Home versus In-Center Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (8) , 1786-1788
Risk of Vascular Access–Related Infections in Home versus In-Center Hemodialysis
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 30 September 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (11) , 1662-1668
Associations of Patient Activation with Outcomes among Patients on Chronic Hemodialysis: A Retrospective, Longitudinal, Observational Study
Key Points: The study explores the potential utility of the Patient Activation Measure 13-item survey as a marker for identifying high-risk patients in the dialysis population. Patient activation had a significant association with mortality. However, no association was observed with hospital admission or markers of adherence. The findings emphasize the need for further studies to validate patient activation in patients on dialysis and its role in improving patient outcomes. Background: Patient activation, defined as an individual's readiness, willingness, and ability to manage their own health and health care, is associated with healthy behaviors and improved outcomes. Patients undergoing in-center hemodialysis have low activation, but the association of patient activation with clinical outcomes among patients on dialysis is unclear. We investigated the association between patient activation and outcomes in patients on hemodialysis. Methods: This cohort included 925 prevalent patients on in-center hemodialysis in ten facilities in a mid-size dialysis provider. All patients who completed the Patient Activation Measure 13-item (PAM-13) survey during a previous study were included, and their records were cross-referenced with data from the electronic heath system. Patients were followed for 180 days after completion of the survey for the primary outcomes of (1) time to death and (2) time to hospitalization. Markers of nonadherence during the months before and after completion of the PAM survey were examined as secondary outcomes, including (1) serum potassium >5.0 mEq/L; (2) serum phosphorus >5.5 mg/dl; (3) missed dialysis treatment because of absence (no hospitalization); and (4) interdialytic weight gain >4.0%. Univariate and adjusted regression models were fit to estimate associations of a three-point increment in PAM-13 score with the outcomes of interest; adjustment factors comprised age, sex, dialysis vintage, serum albumin, diabetes, and hospitalization history. Results: A three-point increment in PAM score was associated with lower hazard of death (univariate hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.84 to 0.94; adjusted HR, 0.90; 95% CI, 0.85 to 0.96), but not with hospitalization (univariate HR, 0.99; 95% CI, 0.96 to 1.02; adjusted HR, 0.99; 95% CI, 0.96 to 1.02). Higher scores were associated with increased odds of having high phosphorus levels in the unadjusted analysis, but this was attenuated and not significant in adjusted models. There were no significant relationships between a three-point increment in PAM score and any of the other secondary outcomes in univariate and adjusted analyses. Conclusions: In a cohort of patients on prevalent, in-center hemodialysis, low activation was associated with mortality, but not with hospitalization or measures of nonadherence.
- 30 September 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (11) , 1662-1668
Open AccessAssociations of Patient Activation with Outcomes among Patients on Chronic Hemodialysis: A Retrospective, Longitudinal, Observational Study
Key Points: The study explores the potential utility of the Patient Activation Measure 13-item survey as a marker for identifying high-risk patients in the dialysis population. Patient activation had a significant association with mortality. However, no association was observed with hospital admission or markers of adherence. The findings emphasize the need for further studies to validate patient activation in patients on dialysis and its role in improving patient outcomes. Background: Patient activation, defined as an individual's readiness, willingness, and ability to manage their own health and health care, is associated with healthy behaviors and improved outcomes. Patients undergoing in-center hemodialysis have low activation, but the association of patient activation with clinical outcomes among patients on dialysis is unclear. We investigated the association between patient activation and outcomes in patients on hemodialysis. Methods: This cohort included 925 prevalent patients on in-center hemodialysis in ten facilities in a mid-size dialysis provider. All patients who completed the Patient Activation Measure 13-item (PAM-13) survey during a previous study were included, and their records were cross-referenced with data from the electronic heath system. Patients were followed for 180 days after completion of the survey for the primary outcomes of (1) time to death and (2) time to hospitalization. Markers of nonadherence during the months before and after completion of the PAM survey were examined as secondary outcomes, including (1) serum potassium >5.0 mEq/L; (2) serum phosphorus >5.5 mg/dl; (3) missed dialysis treatment because of absence (no hospitalization); and (4) interdialytic weight gain >4.0%. Univariate and adjusted regression models were fit to estimate associations of a three-point increment in PAM-13 score with the outcomes of interest; adjustment factors comprised age, sex, dialysis vintage, serum albumin, diabetes, and hospitalization history. Results: A three-point increment in PAM score was associated with lower hazard of death (univariate hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.84 to 0.94; adjusted HR, 0.90; 95% CI, 0.85 to 0.96), but not with hospitalization (univariate HR, 0.99; 95% CI, 0.96 to 1.02; adjusted HR, 0.99; 95% CI, 0.96 to 1.02). Higher scores were associated with increased odds of having high phosphorus levels in the unadjusted analysis, but this was attenuated and not significant in adjusted models. There were no significant relationships between a three-point increment in PAM score and any of the other secondary outcomes in univariate and adjusted analyses. Conclusions: In a cohort of patients on prevalent, in-center hemodialysis, low activation was associated with mortality, but not with hospitalization or measures of nonadherence.
- Open Access
- 1 February 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (2) , 205-215
Cardiovascular Outcomes in Patients on Home Hemodialysis and Peritoneal Dialysis
Key Points: Home hemodialysis is associated with decreased risk of stroke and acute coronary syndrome relative to peritoneal dialysis. Home hemodialysis is associated with decreased risk of cardiovascular death and all-cause death relative to peritoneal dialysis. Background: Cardiovascular disease is the leading cause of morbidity and mortality in patients with ESKD. Little is known about differences in cardiovascular outcomes between home hemodialysis (HHD) and peritoneal dialysis (PD). Methods: We evaluated 68,645 patients who initiated home dialysis between January 1, 2005, and December 31, 2018, using the United States Renal Data System with linked Medicare claims. Rates for incident cardiovascular events of acute coronary syndrome, heart failure, and stroke hospitalizations were determined. Using adjusted time-to-event models, the associations of type of home dialysis modality with the outcomes of incident cardiovascular events, cardiovascular death, and all-cause death were examined. Results: Mean age of patients in the study cohort was 64±15 years, and 42.3% were women. The mean time of follow-up was 1.8±1.6 years. The unadjusted cardiovascular event rate was 95.1 per thousand person-years (PTPY) (95% confidence interval [CI], 93.6 to 96.8), with a higher rate in patients on HHD than on PD (127.8 PTPY; 95% CI, 118.9 to 137.2 versus 93.3 PTPY; 95% CI, 91.5 to 95.1). However, HHD was associated with a slightly lower adjusted risk of cardiovascular events than PD (hazard ratio [HR], 0.92; 95% CI, 0.85 to 0.997). Compared with patients on PD, patients on HHD had 42% lower adjusted risk of stroke (HR, 0.58; 95% CI, 0.48 to 0.71), 17% lower adjusted risk of acute coronary syndrome (HR, 0.83; 95% CI, 0.72 to 0.95), and no difference in risk of heart failure (HR, 1.05; 95% CI, 0.94 to 1.16). HHD was associated with 22% lower adjusted risk of cardiovascular death (HR, 0.78; 95% CI, 0.71 to 0.86) and 8% lower adjusted risk of all-cause death (HR, 0.92; 95% CI, 0.87 to 0.97) as compared with PD. Conclusions: Relative to PD, HHD is associated with decreased risk of stroke, acute coronary syndrome, cardiovascular death, and all-cause death. Further studies are needed to better understand the factors associated with differences in cardiovascular outcomes by type of home dialysis modality in patients with kidney failure.
- 1 February 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (2) , 205-215
Open AccessCardiovascular Outcomes in Patients on Home Hemodialysis and Peritoneal Dialysis
Key Points: Home hemodialysis is associated with decreased risk of stroke and acute coronary syndrome relative to peritoneal dialysis. Home hemodialysis is associated with decreased risk of cardiovascular death and all-cause death relative to peritoneal dialysis. Background: Cardiovascular disease is the leading cause of morbidity and mortality in patients with ESKD. Little is known about differences in cardiovascular outcomes between home hemodialysis (HHD) and peritoneal dialysis (PD). Methods: We evaluated 68,645 patients who initiated home dialysis between January 1, 2005, and December 31, 2018, using the United States Renal Data System with linked Medicare claims. Rates for incident cardiovascular events of acute coronary syndrome, heart failure, and stroke hospitalizations were determined. Using adjusted time-to-event models, the associations of type of home dialysis modality with the outcomes of incident cardiovascular events, cardiovascular death, and all-cause death were examined. Results: Mean age of patients in the study cohort was 64±15 years, and 42.3% were women. The mean time of follow-up was 1.8±1.6 years. The unadjusted cardiovascular event rate was 95.1 per thousand person-years (PTPY) (95% confidence interval [CI], 93.6 to 96.8), with a higher rate in patients on HHD than on PD (127.8 PTPY; 95% CI, 118.9 to 137.2 versus 93.3 PTPY; 95% CI, 91.5 to 95.1). However, HHD was associated with a slightly lower adjusted risk of cardiovascular events than PD (hazard ratio [HR], 0.92; 95% CI, 0.85 to 0.997). Compared with patients on PD, patients on HHD had 42% lower adjusted risk of stroke (HR, 0.58; 95% CI, 0.48 to 0.71), 17% lower adjusted risk of acute coronary syndrome (HR, 0.83; 95% CI, 0.72 to 0.95), and no difference in risk of heart failure (HR, 1.05; 95% CI, 0.94 to 1.16). HHD was associated with 22% lower adjusted risk of cardiovascular death (HR, 0.78; 95% CI, 0.71 to 0.86) and 8% lower adjusted risk of all-cause death (HR, 0.92; 95% CI, 0.87 to 0.97) as compared with PD. Conclusions: Relative to PD, HHD is associated with decreased risk of stroke, acute coronary syndrome, cardiovascular death, and all-cause death. Further studies are needed to better understand the factors associated with differences in cardiovascular outcomes by type of home dialysis modality in patients with kidney failure.
- 11 November 2023
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 83 (1) , 6-8
Kidney Failure in the Court of Chronic Diseases
- 11 November 2023
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 83 (1) , 6-8
Kidney Failure in the Court of Chronic Diseases
- 17 October 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (1) , 85-93
Peritoneal Dialysis Catheter Complications after Insertion by Surgeons, Radiologists, or Nephrologists
Significance Statement: The Advancing American Kidney Health Initiative aims to increase rates of utilization of peritoneal dialysis (PD) in the United States. One of the first steps to PD is successful catheter placement, which can be performed by surgeons, interventional radiologists, or nephrologists. We examined the association between operator subspecialty and risk of needing a follow-up procedure in the first 90 days after initial PD catheter implantation. Overall, we found that 15.5% of catheters required revision, removal, or a second catheter placement within 90 days. The odds of requiring a follow-up procedure was 36% higher for interventional radiologists and 86% higher for interventional nephrologists compared with general surgeons. Further research is needed to understand how to optimize the function of catheters across different operator types. Background: The US government has implemented incentives to increase the use of PD. Successful placement of PD catheters is an important step to increasing PD utilization rates. Our objective was to compare initial outcomes after PD catheter placement by different types of operators. Methods: We included PD-naïve patients insured by Medicare who had a PD catheter inserted between 2010 and 2019. We examined the association between specialty of the operator (general surgeon, vascular surgeon, interventional radiologist, or interventional nephrologist) and odds of needing a follow-up procedure, which we defined as catheter removal, replacement, or revision within 90 days of the initial procedure. Mixed logistic regression models clustered by operator were used to examine the association between operator type and outcomes. Results: We included 46,973 patients treated by 5205 operators (71.1% general surgeons, 17.2% vascular surgeons, 9.7% interventional radiologists, 2.0% interventional nephrologists). 15.5% of patients required a follow-up procedure within 90 days of the initial insertion, of whom 2.9% had a second PD catheter implanted, 6.6% underwent PD catheter removal, and 5.9% had a PD catheter revision within 90 days of the initial insertion. In models adjusted for patient and operator characteristics, the odds of requiring a follow-up procedure within 90 days were highest for interventional nephrologists (HR, 1.86; 95% confidence interval [CI], 1.56 to 2.22) and interventional radiologists (odds ratio, 1.36; 95% CI, 1.17 to 1.58) followed by vascular surgeons (odds ratio, 1.06; 95% CI, 0.97 to 1.14) compared with general surgeons. Conclusions: The probability of needing a follow-up procedure after initial PD catheter placement varied by operator specialty and was higher for interventionalists and lowest for general surgeons.
- 17 October 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35 (1) , 85-93
Peritoneal Dialysis Catheter Complications after Insertion by Surgeons, Radiologists, or Nephrologists
Significance Statement: The Advancing American Kidney Health Initiative aims to increase rates of utilization of peritoneal dialysis (PD) in the United States. One of the first steps to PD is successful catheter placement, which can be performed by surgeons, interventional radiologists, or nephrologists. We examined the association between operator subspecialty and risk of needing a follow-up procedure in the first 90 days after initial PD catheter implantation. Overall, we found that 15.5% of catheters required revision, removal, or a second catheter placement within 90 days. The odds of requiring a follow-up procedure was 36% higher for interventional radiologists and 86% higher for interventional nephrologists compared with general surgeons. Further research is needed to understand how to optimize the function of catheters across different operator types. Background: The US government has implemented incentives to increase the use of PD. Successful placement of PD catheters is an important step to increasing PD utilization rates. Our objective was to compare initial outcomes after PD catheter placement by different types of operators. Methods: We included PD-naïve patients insured by Medicare who had a PD catheter inserted between 2010 and 2019. We examined the association between specialty of the operator (general surgeon, vascular surgeon, interventional radiologist, or interventional nephrologist) and odds of needing a follow-up procedure, which we defined as catheter removal, replacement, or revision within 90 days of the initial procedure. Mixed logistic regression models clustered by operator were used to examine the association between operator type and outcomes. Results: We included 46,973 patients treated by 5205 operators (71.1% general surgeons, 17.2% vascular surgeons, 9.7% interventional radiologists, 2.0% interventional nephrologists). 15.5% of patients required a follow-up procedure within 90 days of the initial insertion, of whom 2.9% had a second PD catheter implanted, 6.6% underwent PD catheter removal, and 5.9% had a PD catheter revision within 90 days of the initial insertion. In models adjusted for patient and operator characteristics, the odds of requiring a follow-up procedure within 90 days were highest for interventional nephrologists (HR, 1.86; 95% confidence interval [CI], 1.56 to 2.22) and interventional radiologists (odds ratio, 1.36; 95% CI, 1.17 to 1.58) followed by vascular surgeons (odds ratio, 1.06; 95% CI, 0.97 to 1.14) compared with general surgeons. Conclusions: The probability of needing a follow-up procedure after initial PD catheter placement varied by operator specialty and was higher for interventionalists and lowest for general surgeons.
- 28 September 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (12) , 1949-1951
Initial Management and Potential Opportunities to Deprescribe Dialysis among Patients with AKI-D Patients after Hospital Discharge
Significance Statement: Dialysis-requiring AKI (AKI-D) now accounts for more than 15% of outpatient hemodialysis initiations; over 30% of these patients with AKI-D may have potential to recover. However, little is known about strategies currently used to treat outpatient AKI-D and screen for recovery. In this study of 1754 patients with AKI-D, we found that ( 1 ) the initial dialysis orders were similar to those of patients with contemporary incident ESKD, despite different treatment goals; ( 2 ) timed urine collections were completed in only a minority of patients; and ( 3 ) most patients with AKI-D who recovered discontinued dialysis without ever having been weaned from their initial dialysis prescription, suggesting there may be substantial opportunity to wean dialysis sooner.
- 28 September 2023
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 34 (12) , 1949-1951
Initial Management and Potential Opportunities to Deprescribe Dialysis among Patients with AKI-D Patients after Hospital Discharge
Significance Statement: Dialysis-requiring AKI (AKI-D) now accounts for more than 15% of outpatient hemodialysis initiations; over 30% of these patients with AKI-D may have potential to recover. However, little is known about strategies currently used to treat outpatient AKI-D and screen for recovery. In this study of 1754 patients with AKI-D, we found that ( 1 ) the initial dialysis orders were similar to those of patients with contemporary incident ESKD, despite different treatment goals; ( 2 ) timed urine collections were completed in only a minority of patients; and ( 3 ) most patients with AKI-D who recovered discontinued dialysis without ever having been weaned from their initial dialysis prescription, suggesting there may be substantial opportunity to wean dialysis sooner.
- Open Access
- 7 September 2023
- Published by Elsevier in Kidney International Reports
- Vol. 8 (12) , 2616-2624
Contemporary Practice of Anemia Treatment Among Dialysis Patients in the United States
- 7 September 2023
- Published by Elsevier in Kidney International Reports
- Vol. 8 (12) , 2616-2624
Open AccessContemporary Practice of Anemia Treatment Among Dialysis Patients in the United States
- 21 August 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (11) , 1490-1496
Setting Up Home Dialysis Programs
Home dialysis utilization has been growing in the United States over the past decade but still lags behind similar socioeconomic nations. More than half of dialysis facilities in the United States either are not licensed to offer home dialysis or, despite a license, have no patients dialyzing at home, and many programs have a relatively small census. Multiple stakeholders, including patients, health care providers, and payers, have identified increased home dialysis use as an important goal. To realize these goals, nephrologists and kidney care professionals need a sound understanding of the key considerations in home dialysis center operation. In this review, we outline the core domains required to set up and operate a home dialysis program in the United States now and in the future.
- 21 August 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (11) , 1490-1496
Setting Up Home Dialysis Programs
Home dialysis utilization has been growing in the United States over the past decade but still lags behind similar socioeconomic nations. More than half of dialysis facilities in the United States either are not licensed to offer home dialysis or, despite a license, have no patients dialyzing at home, and many programs have a relatively small census. Multiple stakeholders, including patients, health care providers, and payers, have identified increased home dialysis use as an important goal. To realize these goals, nephrologists and kidney care professionals need a sound understanding of the key considerations in home dialysis center operation. In this review, we outline the core domains required to set up and operate a home dialysis program in the United States now and in the future.
- 27 July 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (11) , 1483-1489
Increased Access, Persistent Disparities
Peritoneal dialysis (PD) use has increased in the United States since 2009, but how this has affected disparities in PD use is unclear. We used data from the United States Renal Data System to identify a cohort of incident dialysis patients from 2009 to 2019. We used logistic regression models to examine how odds of PD use changed by demographic characteristics. The incident PD population increased by 203% from 2009 to 2019, and the odds of PD use increased in every subgroup. PD use increased more among older people because the odds for those aged 75 years or older increased 15% more per 5-year period compared with individuals aged 18–44 years (odds ratio [OR] 1.68, 95% confidence interval [CI], 1.64 to 1.73 versus OR 1.46, 95% CI, 1.42 to 1.50). The odds of PD use increased 5% more per 5-year period among Hispanic people compared with White people (OR 1.58, 95% CI, 1.53 to 1.63 versus OR 1.51, 95% CI, 1.48 to 1.53). There was no difference in odds of PD initiation among people who were Black, Asian, or of another race. The odds of PD use increased 5% more for people living in urban areas compared with people living in nonurban areas (5-year OR 1.54, 95% CI, 1.52 to 1.56 versus 5-year OR 1.46, 95% CI, 1.42 to 1.50). The odds of PD use increased 7% more for people living in socioeconomically advantaged areas compared with people living in more deprived areas (5-year OR 1.60, 95% CI, 1.56 to 1.63 for neighborhoods with lowest Social Deprivation Index versus 5-year OR 1.50, 95% CI, 1.48 to 1.53 in the most deprived areas). Expansion of PD use led to a reduction in disparities for older people and for Hispanic people. Although PD use increased across all strata of socioeconomic deprivation, the gap in PD use between people living in the least deprived areas and those living in the most deprived areas widened.
- 27 July 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 18 (11) , 1483-1489
Increased Access, Persistent Disparities
Peritoneal dialysis (PD) use has increased in the United States since 2009, but how this has affected disparities in PD use is unclear. We used data from the United States Renal Data System to identify a cohort of incident dialysis patients from 2009 to 2019. We used logistic regression models to examine how odds of PD use changed by demographic characteristics. The incident PD population increased by 203% from 2009 to 2019, and the odds of PD use increased in every subgroup. PD use increased more among older people because the odds for those aged 75 years or older increased 15% more per 5-year period compared with individuals aged 18–44 years (odds ratio [OR] 1.68, 95% confidence interval [CI], 1.64 to 1.73 versus OR 1.46, 95% CI, 1.42 to 1.50). The odds of PD use increased 5% more per 5-year period among Hispanic people compared with White people (OR 1.58, 95% CI, 1.53 to 1.63 versus OR 1.51, 95% CI, 1.48 to 1.53). There was no difference in odds of PD initiation among people who were Black, Asian, or of another race. The odds of PD use increased 5% more for people living in urban areas compared with people living in nonurban areas (5-year OR 1.54, 95% CI, 1.52 to 1.56 versus 5-year OR 1.46, 95% CI, 1.42 to 1.50). The odds of PD use increased 7% more for people living in socioeconomically advantaged areas compared with people living in more deprived areas (5-year OR 1.60, 95% CI, 1.56 to 1.63 for neighborhoods with lowest Social Deprivation Index versus 5-year OR 1.50, 95% CI, 1.48 to 1.53 in the most deprived areas). Expansion of PD use led to a reduction in disparities for older people and for Hispanic people. Although PD use increased across all strata of socioeconomic deprivation, the gap in PD use between people living in the least deprived areas and those living in the most deprived areas widened.